ArticleInternational journal of nanomedicine2019
Article in International journal of nanomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Amyloid-β PET in Alzheimer's disease: A systematic review and Bayesian meta-analysis.Brain and behavior · 2023Pooled it
- Radiolabeled Iron-Based Nanomaterials for Cancer Diagnosis and Therapy.International journal of nanomedicine · 2026Review
- Multimodal imaging in cancer detection: the role of SPIONs and USPIONs as contrast agents for MRI, SPECT, and PET.Future oncology (London, England) · 2025Review
- Nanoradiopharmaceuticals: Design Principles, Radiolabeling Strategies, and Biomedicine Applications.Pharmaceutics · 2025Review
- Article
- Diagnosis and treatment status of inoperable locally advanced breast cancer and the application value of inorganic nanomaterials.Journal of nanobiotechnology · 2024Review
- Nanostrategies for Therapeutic and Diagnostic Targeting of Gastrin-Releasing Peptide Receptor.International journal of molecular sciences · 2023Review
- Radiolabeled Iron Oxide Nanoparticles as Dual Modality Contrast Agents in SPECT/MRI and PET/MRI.Nanomaterials (Basel, Switzerland) · 2023Review
- Preclinical PET and MR Evaluation ofNanomaterials (Basel, Switzerland) · 2022Article
- Toxicity Assessment of [Nanomaterials (Basel, Switzerland) · 2022Article
- Methods for Radiolabelling Nanoparticles: PET Use (Part 2).Biomolecules · 2022Review
- IAEA Contribution to Nanosized Targeted Radiopharmaceuticals for Drug Delivery.Pharmaceutics · 2022Review
- Biomedical Applications of Iron Oxide Nanoparticles: Current Insights Progress and Perspectives.Pharmaceutics · 2022Review
- Trimethyl-Chitosan Coated Gold Nanoparticles Enhance Delivery, Cellular Uptake and Gene Silencing Effect of EGFR-siRNA in Breast Cancer Cells.Frontiers in molecular biosciences · 2022Article
- Synthesis and Properties of Targeted Radioisotope Carriers Based on Poly(Acrylic Acid) Nanogels.Pharmaceutics · 2021Article
- Transarterial Radioembolization Agents: a Review of the Radionuclide Agents and the Carriers.Nuclear medicine and molecular imaging · 2021Review
- Imaging Constructs: The Rise of Iron Oxide Nanoparticles.Molecules (Basel, Switzerland) · 2021Review
- Recent nanotheranostics applications for cancer therapy and diagnosis: A review.IET nanobiotechnology · 2021Review
- Advances in Development of Radiometal Labeled Amino Acid-Based Compounds for Cancer Imaging and Diagnostics.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Water-Soluble Chitosan Conjugated DOTA-Bombesin Peptide Capped Gold Nanoparticles as a Targeted Therapeutic Agent for Prostate Cancer.Nanotechnology, science and applications · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNowadays, nanoparticles (NPs) have attracted much attention in biomedical imaging due to their unique magnetic and optical characteristics. Superparamagnetic iron oxide nanoparticles (SPIONs) are the prosperous group of NPs with the capability to apply as magnetic resonance imaging (MRI) contrast agents. Radiolabeling of targeted SPIONs with positron emitters can develop dual positron emission tomography (PET)/MRI agents to achieve better diagnosis of clinical conditions.
methodsIn this work,
resultsThe DOTA-BN-TMC-MNPs with a particle size between 20 and 30 nm were efficiently labeled with
conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.